Latest news with #ZYN
Business Wire
2 days ago
- Business
- Business Wire
Philip Morris International to Host Webcast of 2025 Second-Quarter and First-Half Results
STAMFORD, CT--(BUSINESS WIRE)--Regulatory News: Philip Morris International Inc. (PMI) (NYSE: PM) will host a live audio webcast at on Tuesday, July 22, 2025, at 9:00 a.m. ET, to discuss its 2025 second-quarter and first-half results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast will be hosted by Emmanuel Babeau, Chief Financial Officer, and will include discussion of PMI's financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI's Investor Relations App at The webcast recording and the slides and script will be available at The recording will be available for one year post-event. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. As of December 31, 2024, PMI's smoke-free products were available for sale in 95 markets, and PMI estimates they were used by 38.6 million adults around the world. The smoke-free business accounted for 42% of PMI's first-quarter 2025 total net revenues. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches and versions of PMI's IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product authorizations from the FDA. With a strong foundation and significant expertise in life sciences, PMI has a long-term ambition to expand into wellness and healthcare areas and aims to enhance life through the delivery of seamless health experiences. References to 'PMI', 'we', 'our' and 'us' mean Philip Morris International Inc., and its subsidiaries. For more information, please visit and
Yahoo
2 days ago
- Business
- Yahoo
Philip Morris International (PM): A Bull Case Theory
We came across a bullish thesis on Philip Morris International on WorldlyInvest's Substack. As of 2ⁿᵈ July, Philip Morris International's share was trading at $175.91. PM's trailing and forward P/E were 27.70 and 24.43 respectively according to Yahoo Finance. Diego Cervo/ Russo views Philip Morris International (PM) as one of the most remarkable examples in the author's portfolio of a company with the capacity to reinvest and transform itself. Over the past 14 years, PM has invested aggressively into developing Reduced Risk Products (RRPs) like IQOS, VEEV ONE, and ZYN. IQOS, its flagship heat-not-burn product, is now a major success in Japan and expanding in Western Europe. The regulatory backdrop is improving, with ZYN recently gaining FDA recognition as reduced-risk. PM's deep investments are creating network effects in its RRPs ecosystem, where scale, retail presence, and consumer loyalty drive competitive advantage. Russo sees PM as having built a durable path to grow nicotine market share in safer formats — aligning both with societal trends and future revenue/profit growth. PM's capacity to suffer — making $14B+ in RRP investments ahead of peers — positions it as the clear leader in the industry's future. The company's investments in innovation and renovation of their product lineup, underwritten cumulative smoke-free product investments of $14 billion, growing sharply from a smaller base of $2.4 billion in 2015, make it an attractive investment. Previously, we covered a on Philip Morris International by Librarian Capital in June 2025, which highlighted the company's potential as a backdoor play on the AI energy boom through its nuclear energy infrastructure assets. The stock has depreciated by 1.90% since then. This previous thesis emphasized PM's critical energy infrastructure and potential to profit from the AI energy spike, but it didn't play out as AI focus shifted. WorldlyInvest's current thesis shares a similar view on PM's growth potential, but emphasizes its successful transformation through investments in Reduced Risk Products like IQOS and ZYN, positioning it for future revenue growth. PM isn't on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of PM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Philip Morris International (PM): A Bull Case Theory
We came across a bullish thesis on Philip Morris International on WorldlyInvest's Substack. As of 2ⁿᵈ July, Philip Morris International's share was trading at $175.91. PM's trailing and forward P/E were 27.70 and 24.43 respectively according to Yahoo Finance. Diego Cervo/ Russo views Philip Morris International (PM) as one of the most remarkable examples in the author's portfolio of a company with the capacity to reinvest and transform itself. Over the past 14 years, PM has invested aggressively into developing Reduced Risk Products (RRPs) like IQOS, VEEV ONE, and ZYN. IQOS, its flagship heat-not-burn product, is now a major success in Japan and expanding in Western Europe. The regulatory backdrop is improving, with ZYN recently gaining FDA recognition as reduced-risk. PM's deep investments are creating network effects in its RRPs ecosystem, where scale, retail presence, and consumer loyalty drive competitive advantage. Russo sees PM as having built a durable path to grow nicotine market share in safer formats — aligning both with societal trends and future revenue/profit growth. PM's capacity to suffer — making $14B+ in RRP investments ahead of peers — positions it as the clear leader in the industry's future. The company's investments in innovation and renovation of their product lineup, underwritten cumulative smoke-free product investments of $14 billion, growing sharply from a smaller base of $2.4 billion in 2015, make it an attractive investment. Previously, we covered a on Philip Morris International by Librarian Capital in June 2025, which highlighted the company's potential as a backdoor play on the AI energy boom through its nuclear energy infrastructure assets. The stock has depreciated by 1.90% since then. This previous thesis emphasized PM's critical energy infrastructure and potential to profit from the AI energy spike, but it didn't play out as AI focus shifted. WorldlyInvest's current thesis shares a similar view on PM's growth potential, but emphasizes its successful transformation through investments in Reduced Risk Products like IQOS and ZYN, positioning it for future revenue growth. PM isn't on our list of the 30 Most Popular Stocks Among Hedge Funds. While we acknowledge the risk and potential of PM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
Stifel Rates Philip Morris (PM) as a ‘Buy' Buoyed By Smoke-Free Strategy
Philip Morris International Inc. (NYSE:) is . On June 30, analysts at Stifel reiterated a 'Buy' rating on the stock and a $186 price target. The bullish stance comes as the stock has registered an impressive 46% year-to-date gain while maintaining an industry-leading gross profit margin of 65.68%. Copyright: kophoto / 123RF Stock Photo Analysts at Stifel expect an increased focus on the European market to contribute approximately one-third of the company's smoke-free growth through 2026. They also expect the company to benefit from the momentum of IQOS and the development of a multi-category strategy, including VEEV e-vapor and ZYN pouches. Stifel maintains a positive bias towards Philip Morris due to its multi-category approach, which focuses on smoke-free products. It expects the strategy to allow the company to capture and drive incremental consumer shifts beyond heated tobacco. Philip Morris International Inc. (NYSE:PM) is a leading international tobacco company that is transitioning to a smoke-free future. While it still produces and sells cigarettes, PMI is heavily investing in and promoting smoke-free alternatives like heated tobacco, e-vapor, and oral smokeless products. While we acknowledge the potential of PM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Nuclear Energy Stocks to Invest in for the Next Decade and 10 Best Healthcare Penny Stocks to Buy According to Analysts. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Forbes
04-07-2025
- Health
- Forbes
Rise In Teen Use Of Nicotine Pouches In U.S. Has Some Experts Alarmed
In this photo illustration, Zyn nicotine cases and pouches are shown.(Photo Illustration by Michael ... More M. Santiago/Getty Images) The Food and Drug Administration authorized the marketing of ZYN nicotine pouch products earlier this year. The agency found that the pouches provide potential health benefits which are 'sufficient to outweigh the risks of the products, including to youth.' At the same time, the agency said it would 'closely monitor youth use.' The pouches are small sachets of nicotine and additives that are placed between the gum and lip. The stimulant is then absorbed into the bloodstream. Pouches have been available for over a decade, but the FDA's marketing authorization of ZYN marks the first time regulators in America have formally endorsed their sale. By providing nicotine to users without the harms from cigarette smoking, the pouches are now formally considered by the FDA to be a harm reduction aid for smokers who wish to quit and reduce exposure to toxic substances. But many who consume these pouches are not smokers and a growing number are not adults. The high nicotine content can lead to addiction, along with potential risks to both cardiovascular and oral health. Overall, Nielsen Scan Track shows that 'monthly Oral Nicotine Pouch unit sales increased significantly, from 327 million in July 2021 to 1046 million in May 2024—more than tripling over this period.' Philip Morris International shipped 202 million cans of ZYN in the first quarter of 2025, up 53% from the same period in 2024. As smoking rates have fallen in the United States and elsewhere, the tobacco industry is aiming to diversify the set of products it sells and this includes nicotine pouches. The company sponsor of ZYN notes that it is committed to responsible marketing practices focused on limiting access in the U.S. to adults 21 years of age and older. The firm does not use social media influencers in the U.S. or people under the age of 35 in promotional materials. Nevertheless, recent data show that use of such products has nearly doubled among teenagers from 2023 to 2024. A newly released Journal of the American Medical Association study shows that nicotine pouches are gaining traction among high school students. Out of more than 10,000 10th- and 12th-grade students, 5.4% said in 2024 they had used nicotine pouches at some point in their lives, compared to just 3% saying the same in 2023, and 2.6% said in 2024 they'd used them in the past month, compared to 1.3% in 2023. Despite not being condoned by the product's manufacturer, social media influencers appear to be aimed at appealing to younger Americans. There's an apparent attractiveness to a product that isn't carcinogenic—at least not proven—and is smokeless. It's also thought that the release of dopamine caused by nicotine may help with mental acuity. But the FDA warned that its marketing authorization does not mean that the products are necessarily safe. When the FDA authorized the sale of 20 Zyn products in flavors like coffee, citrus, and cinnamon in January of this year, it noted it could revoke that permission if there was a substantial rise in youth uptake. As with e-cigarettes before them, researchers are monitoring how young people in particular are adopting what some warn are highly addictive products. ZYN pouches deliver high doses of nicotine, raising concerns among experts about addiction, possible dual use with other tobacco products and possible long-term health consequences. Among other concerned groups, the American Heart Association put out a statement that evaluates the latest published research on these products, their use patterns among youth and adults and the potential health threats they pose. Nicotine can have negative cardiovascular effects, including heightened blood pressure, heart rate and cholesterol. Furthermore, some pouch users have said they suffer from mouth lesions from long-term use. Some experts believe that ZYN nicotine pouches could present an emerging public health concern, especially among adolescents and young adults. Senate Minority Leader Chuck Schumer formally asked the FDA in 2024 to investigate ZYN and its potential effect on teens. Pending future research findings, more monitoring may be needed. In turn, this could lead to an expanded set of regulations together with a more visible public health campaign that issues targeted warnings for youth about possible risks associated with nicotine pouch use.
